A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Eribulin (Primary)
Indications Advanced breast cancer; Carcinoma; Inflammatory breast cancer; Triple negative breast cancer
Focus Therapeutic Use

12 Sep 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
12 Sep 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
09 Dec 2023 Status changed from active, no longer recruiting to discontinueddue to lack of efficacy in cohort 2 and the changing landscape of metastatic breast cancer therapies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com